Sanofi $SNY Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. lifted its holdings in Sanofi (NASDAQ:SNY) by 4.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 374,816 shares of the company’s stock after acquiring an additional 14,325 shares during the quarter. Cibc World Market Inc.’s holdings in Sanofi were worth $17,691,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Brighton Jones LLC boosted its stake in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Sanofi by 107.2% in the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares in the last quarter. Sivia Capital Partners LLC grew its position in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new position in Sanofi in the second quarter valued at $28,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $47.03 on Friday. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a market cap of $114.71 billion, a P/E ratio of 13.06, a P/E/G ratio of 1.28 and a beta of 0.45. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20. The company’s 50-day moving average price is $47.80 and its 200-day moving average price is $48.62.

More Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi completed its acquisition of Dynavax, strengthening its adult vaccine portfolio (adds CpG-adjuvant technology and vaccine candidates that could boost medium‑term commercial and pipeline prospects). Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi’s board named Belén Garijo as CEO in a formal appointment/press release — markets will be watching her near-term communications, strategy priorities and any shifts in R&D or capital allocation. Who is Sanofi’s new CEO Belén Garijo?
• Neutral Sentiment: Trading activity is elevated (roughly 10.8M shares vs ~4.2M average), indicating heavy repositioning; elevated volume can amplify volatility while investors digest corporate governance and strategy signals. Sanofi downgrade note
• Negative Sentiment: The board’s decision not to renew Paul Hudson’s mandate was widely reported as an abrupt ouster, creating headline-driven uncertainty about leadership stability and execution risk — selling pressure followed those reports. Sanofi tumbles after board shockingly ousts CEO Paul Hudson
• Negative Sentiment: Bank of America downgraded Sanofi from Buy to Neutral, which can reduce buy-side conviction and remove a source of upward price support in the near term. Sanofi downgraded by Bank of America

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of analyst reports. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. HSBC restated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Citigroup started coverage on shares of Sanofi in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.